{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015527","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.882476+00:00","generated_at":"2026-06-24T02:34:17.879110+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Acadia Q2 NUPLAZID sales $134.6M (+17% YoY); NDA filed for trofinetide in Rett syndrome","bullets":["Q2 net loss $34.0M ($0.21/share) vs $43.9M loss in Q2 2021; six-month loss $147.1M.","R&D expense $75.6M vs $56.9M YoY; SG&A $89.9M vs $96.8M on lower promo costs.","NDA submitted to FDA for trofinetide for Rett syndrome; CRL received for pimavanserin in Alzheimer's psychosis.","Discontinued development of ACP-044 (pain) and ACP-319 (M1 PAM) based on data review.","2022 NUPLAZID revenue guidance narrowed to $510-540M from $510-560M; R&D guidance reduced."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015527","json":"https://secwatch.observer/filing/0000950170-22-015527.json","markdown":"https://secwatch.observer/filing/0000950170-22-015527.md","text":"https://secwatch.observer/filing/0000950170-22-015527.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017022015527/0000950170-22-015527-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017022015527/acad-20220808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:34:17.879110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}